- Home
- TOI vs IGC Comparison
TOI vs IGC Comparison
Compare TOI & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOI
- IGC
- Stock Information
- Founded
- TOI 2007
- IGC 2005
- Country
- TOI United States
- IGC United States
- Employees
- TOI N/A
- IGC N/A
- Industry
- TOI Medical/Nursing Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- TOI Health Care
- IGC Health Care
- Exchange
- TOI Nasdaq
- IGC Nasdaq
- Market Cap
- TOI 22.7M
- IGC 23.8M
- IPO Year
- TOI N/A
- IGC N/A
- Fundamental
- Price
- TOI $0.35
- IGC $0.41
- Analyst Decision
- TOI Strong Buy
- IGC Strong Buy
- Analyst Count
- TOI 1
- IGC 2
- Target Price
- TOI $2.50
- IGC $3.63
- AVG Volume (30 Days)
- TOI 61.3K
- IGC 710.6K
- Earning Date
- TOI 11-06-2024
- IGC 11-11-2024
- Dividend Yield
- TOI N/A
- IGC N/A
- EPS Growth
- TOI N/A
- IGC N/A
- EPS
- TOI N/A
- IGC N/A
- Revenue
- TOI $361,067,000.00
- IGC $1,062,000.00
- Revenue This Year
- TOI $29.17
- IGC N/A
- Revenue Next Year
- TOI $16.43
- IGC $13.57
- P/E Ratio
- TOI N/A
- IGC N/A
- Revenue Growth
- TOI 23.31
- IGC N/A
- 52 Week Low
- TOI $0.27
- IGC $0.25
- 52 Week High
- TOI $2.66
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- TOI 56.85
- IGC 59.89
- Support Level
- TOI $0.32
- IGC $0.35
- Resistance Level
- TOI $0.39
- IGC $0.41
- Average True Range (ATR)
- TOI 0.02
- IGC 0.02
- MACD
- TOI 0.01
- IGC 0.00
- Stochastic Oscillator
- TOI 51.82
- IGC 67.29
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.